

Ding-wei Ye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5631503/publications.pdf>

Version: 2024-02-01

123
papers

3,791
citations

218677

26
h-index

155660

55
g-index

126
all docs

126
docs citations

126
times ranked

4689
citing authors

#	ARTICLE	IF	CITATIONS
1	Special issue "The advance of solid tumor research in China" Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response. <i>International Journal of Cancer</i> , 2023, 152, 66-78.	5.1	4
2	Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial. <i>Asian Journal of Andrology</i> , 2022, 24, 161.	1.6	7
3	Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 50.	1.6	2
4	Inherited Mutations in Chinese Men With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 54-62.	4.9	13
5	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	4.2	19
6	Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.03.007 . <i>European Urology</i> , 2022, , .	1.9	1
7	The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma. <i>Journal of the National Cancer Center</i> , 2022, 2, 162-170.	7.4	7
8	Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	2.1	6
9	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 802-810.	5.4	22
10	Prevalence of comprehensive <scp>DNA</scp> damage repair gene germline mutations in Chinese prostate cancer patients. <i>International Journal of Cancer</i> , 2021, 148, 673-681.	5.1	20
11	Identification of a methylation panel aid in risk stratification in node-positive penile squamous cell carcinoma. <i>International Journal of Cancer</i> , 2021, 148, 1289-1298.	5.1	1
12	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. <i>European Urology Oncology</i> , 2021, 4, 121-123.	5.4	5
13	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	3.9	62
14	A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	1.3	3
15	Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response. <i>Annals of Medicine</i> , 2021, 53, 596-610.	3.8	13
16	Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study. <i>Asian Journal of Andrology</i> , 2021, 23, 41.	1.6	7
17	Intravesical Recurrence After Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes. <i>Frontiers in Surgery</i> , 2021, 8, 590448.	1.4	8
18	A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 108-108.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11-11.	1.6	6
20	First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 391-391.	1.6	37
21	Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3898-3911.	3.6	10
22	Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing. <i>Oncogene</i> , 2021, 40, 2382-2394.	5.9	8
23	Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Frontiers in Oncology</i> , 2021, 11, 641385.	2.8	1
24	Epidemiology and genomics of prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2021, 18, 282-301.	3.8	111
25	Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	3.6	19
26	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human anti-programmed death-1 monoclonal antibody for advanced solid tumors or lymphoma. <i>European Journal of Cancer</i> , 2021, 148, 1-13.	2.8	9
27	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5068-5068.	1.6	2
28	Association of BMI, body composition and outcomes in Chinese patients with metastatic renal cell carcinoma treated with immunotherapy: A retrospective, multicohort analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16563-e16563.	1.6	0
29	Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2078-2083.	1.4	3
30	The genomic landscape of Chinese patients with upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16583-e16583.	1.6	0
31	Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4550-4550.	1.6	2
32	Genomic characteristics of homologous recombination deficiency in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17004-e17004.	1.6	0
33	ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. <i>Science Advances</i> , 2021, 7, .	10.3	22
34	m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709579.	2.8	10
35	Genetic polymorphisms at 19q13.33 are associated with [âˆ²]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. <i>Prostate</i> , 2021, 81, 971-982.	2.3	4
36	Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation. <i>BMC Cancer</i> , 2021, 21, 857.	2.6	4

#	ARTICLE	IF	CITATIONS
37	ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A. <i>Cell Death and Disease</i> , 2021, 12, 661.	6.3	7
38	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
39	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2294-2303.	1.6	218
40	Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 500.e9-500.e13.	1.6	8
41	Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. <i>Cancer Medicine</i> , 2021, 10, 6697-6704.	2.8	7
42	Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. <i>Clinical Cancer Research</i> , 2021, 27, 5838-5846.	7.0	14
43	Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy. <i>Pathology and Oncology Research</i> , 2021, 27, 1609809.	1.9	2
44	MP30-15 THE COMBINATION OF PROSTATE HEALTH INDEX (PHI) AND MULTIPARAMETRIC MRI PROSTATE IMPROVES THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER (CSPCA): A MULTICENTRE EVALUATION. <i>Journal of Urology</i> , 2021, 206, .	0.4	0
45	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e7-838.e13.	1.6	3
46	Impact of radiation therapy on perineal urethrostomy for penile cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 84-87.	1.7	1
47	Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. <i>Journal of Urology</i> , 2021, 206, 914-923.	0.4	9
48	Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. <i>Journal of Urology</i> , 2021, 206, 960-969.	0.4	8
49	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. <i>Nature Communications</i> , 2021, 12, 5779.	12.8	14
50	Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. <i>International Journal of Biological Sciences</i> , 2021, 17, 2205-2222.	6.4	36
51	Adenylate cyclase-activating polypeptide 1 gene methylation predicts prognosis and the immune microenvironment of bladder cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e597.	4.0	1
52	Systematic Genome-Wide Profiles Reveal Alternative Splicing Landscape and Implications of Splicing Regulator DExD-Box Helicase 21 in Aggressive Progression of Adrenocortical Carcinoma. <i>Phenomics</i> , 2021, 1, 243-256.	2.9	13
53	Comprehensive Multi-Omics Identification of Interferon- γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 734646.	4.8	13
54	LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. <i>Cell Death and Disease</i> , 2021, 12, 1043.	6.3	89

#	ARTICLE	IF	CITATIONS
55	Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. <i>Frontiers in Oncology</i> , 2021, 11, 762547.	2.8	1
56	A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 753920.	2.8	2
57	ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754845.	2.8	8
58	Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis. <i>Current Therapeutic Research</i> , 2021, 95, 100653.	1.2	2
59	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 785410.	3.7	12
60	Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 751977.	2.3	6
61	Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772436.	3.7	8
62	The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. <i>European Urology Focus</i> , 2020, 6, 53-62.	3.1	5
63	Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 1552-1562.	2.6	18
64	Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3124-3134.	2.6	12
65	Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 197-198.	3.9	12
66	A risk calculator predicting recurrence in lymph node metastatic penile cancer. <i>BJU International</i> , 2020, 126, 577-585.	2.5	12
67	Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study. <i>Frontiers in Oncology</i> , 2020, 10, 1521.	2.8	9
68	Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data. <i>Oncolimmunology</i> , 2020, 9, 1784529.	4.6	27
69	Survival after radical cystectomy for bladder cancer: Multicenter comparison between minimally invasive and open approaches. <i>Asian Journal of Urology</i> , 2020, 7, 291-300.	1.2	2
70	<p>High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10453-10464.	2.0	11
71	LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. <i>Cell Death and Disease</i> , 2020, 11, 638.	6.3	26
72	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 527952.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1547-1557.	13.7	546
74	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	2.8	19
75	Large-scale transcriptome profiles reveal robust 20 signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9012-9027.	3.6	28
76	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
77	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. <i>BJU International</i> , 2020, 125, 867-875.	2.5	15
78	Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. <i>BMC Cancer</i> , 2020, 20, 219.	2.6	12
79	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. <i>Oncologist</i> , 2020, 25, e1042-e1050.	3.7	17
80	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 3278-3286.	2.8	3
81	<p>Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1779-1787.	1.9	5
82	The Rare Variant rs35356162 in UHRF1BP1 Increases Bladder Cancer Risk in Han Chinese Population. <i>Frontiers in Oncology</i> , 2020, 10, 134.	2.8	16
83	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. <i>Oncolimmunology</i> , 2020, 9, 1762473.	4.6	33
84	Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 950-961.	2.3	31
85	Development and validation of a mitochondrial metabolism-associated nomogram for prediction of prognosis in clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e120.	4.0	3
86	Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China. <i>European Urology</i> , 2020, 78, 120-122.	1.9	11
87	<p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	1.9	12
88	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. <i>Cancers</i> , 2020, 12, 831.	3.7	11
89	Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 610229.	3.5	18
90	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. <i>Cancer Letters</i> , 2020, 485, 45-55.	7.2	42

#	ARTICLE	IF	CITATIONS
91	Impact of human papillomavirus (HPV) infection on the outcome of perioperative treatments for penile squamous-cell carcinoma (PSCC).. Journal of Clinical Oncology, 2020, 38, 5088-5088.	1.6	2
92	Development of a risk calculator of recurrence in inguinal lymph node metastatic (ILNM) patients with surgically resected penile squamous cell carcinoma (PSCC).. Journal of Clinical Oncology, 2020, 38, 1-1.	1.6	0
93	Germline mutations in DNA repair genes in a large series of unselected Chinese prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, e17523-e17523.	1.6	0
94	A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.. Journal of Clinical Oncology, 2020, 38, e17579-e17579.	1.6	31
95	Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 6047-6047.	1.6	0
96	Treatment patterns and outcomes of patients with penile squamous-cell carcinoma (PSCC) undergoing inguinal lymph node dissection (ILND): An analysis of a multicenter contemporary database.. Journal of Clinical Oncology, 2020, 38, 5585-5585.	1.6	0
97	Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.. Journal of Clinical Oncology, 2020, 38, 5085-5085.	1.6	3
98	Abstract 3275: GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial. , 2020, , .		0
99	Prognostic value of primary tumor surgery in seminoma patients with distant metastasis at diagnosis: a population-based study. Asian Journal of Andrology, 2020, 22, 602.	1.6	1
100	Identification and validation of novel metastasis-related signatures of clear cell renal cell carcinoma using gene expression databases. American Journal of Translational Research (discontinued), 2020, 12, 4108-4126.	0.0	4
101	78â€¦T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. , 2020, , .		0
102	Management of patients with advanced prostate cancer in the Asia Pacific region: â€œrealâ€œworldâ€™ consideration of results from the Advanced Prostate Cancer Consensus Conference <scp>(APCCC)</scp> 2017. BJU International, 2019, 123, 22-34.	2.5	32
103	Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. Journal of Cancer, 2019, 10, 4333-4340.	2.5	23
104	Lowâ€œserum prostateâ€œspecific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate, 2019, 79, 1563-1571.	2.3	12
105	Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 363.	4.4	46
106	Family history is significantly associated with prostate cancer and its early onset in Chinese population. Prostate, 2019, 79, 1762-1766.	2.3	6
107	Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma. Frontiers in Genetics, 2019, 10, 821.	2.3	28
108	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. European Urology, 2019, 76, 280-283.	1.9	41

#	ARTICLE	IF	CITATIONS
109	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 686-700.	10.7	496
110	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. <i>Journal of Cancer</i> , 2019, 10, 4522-4531.	2.5	29
111	A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. <i>European Urology</i> , 2019, 75, 558-561.	1.9	64
112	Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. <i>Aging</i> , 2019, 11, 6999-7020.	3.1	163
113	Identification and Validation of Stromal Immunity Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3069-3078.	7.0	124
114	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
115	An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 634.	2.8	24
116	Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. <i>Asian Journal of Andrology</i> , 2016, 18, 525.	1.6	11
117	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. <i>Nature Communications</i> , 2015, 6, 8469.	12.8	51
118	Prostate cancer in Asia: A collaborative report. <i>Asian Journal of Urology</i> , 2014, 1, 15-29.	1.2	136
119	Visceral fat accumulation is associated with different pathological subtypes of renal cell carcinoma (ccRCC): a multicentre study in China. <i>BJU International</i> , 2014, 114, 496-502.	2.5	15
120	A novel Germline mutation in <i>HOXB13</i> is associated with prostate cancer risk in Chinese men. <i>Prostate</i> , 2013, 73, 169-175.	2.3	70
121	Visceral Obesity and Risk of High Grade Disease in Clinical T1a Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 189, 447-453.	0.4	58
122	Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. <i>Nature Genetics</i> , 2012, 44, 1231-1235.	21.4	160
123	Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4